miR‐26a inhibits proliferation and motility in bladder cancer by targeting HMGA1
Yiwei Lin(First Affiliated Hospital Zhejiang University), Liping Xie(First Affiliated Hospital Zhejiang University), Xianglai Xu(Fudan University), Zhenghui Hu(First Affiliated Hospital Zhejiang University), Hong Chen(Second Affiliated Hospital of Dalian Medical University), Shiqi Li(Zhejiang University), Xin Xu(Dalian Medical University), Yi Zhu(Zhejiang University), Yeqing Mao(First Affiliated Hospital Zhejiang University), Xiangyi Zheng(Tianjin University), Qiqi Mao(First Affiliated Hospital Zhejiang University), Jian Wu(Sun Yat-sen University)
Cited by 89
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276